© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 31, 2022
Dr Chirag A. Shah highlights novel emerging treatments in ovarian cancer and provides advice for community oncologists.
Chirag A. Shah, MD, details his personal clinical experience with using niraparib for ovarian cancer maintenance therapies.
An expert shares data from several clinical trials on the use of PARP inhibitors for maintenance therapies in ovarian cancer.
Dr Chirag A. Shah explains the front-line treatment options for ovarian cancer and the factors considered in choosing maintenance therapies.
A gynecologic oncologist discusses the importance of molecular testing in ovarian cancer and how it influences treatment selection.
Chirag A. Shah, MD, presents and reviews the case of a 59-year-old woman with ovarian cancer.